 |
|
|
|
 |
|
|
| Article 1 to 5 out of 5 concerning Cephalon Inc.
|
-
Cephalon Receives Approval to Market Modafinil for Shift Work Sleep Disorder in Germany
(09/01/2005)
Cephalon, Inc. announced that the company has received authorization from the Federal Institute for Drugs and Devices (BfArM) to market modafinil tablets in Germany for the treatment of moderate to severe chronic shift work sleep disorder with ...
-
Cell Therapeutics Sells TRISENOX(R) to Cephalon. for $70 Million in Cash
(06/15/2005)
CTI Technologies, Inc. (CTIT), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) announced that it has agreed to sell the TRISENOX brand to Cephalon, Inc. Under the terms of the agreement, Cephalon will pay to CTI and its affiliates an ...
-
Cephalon Announces Acquisition of Salmedix
(05/18/2005)
Cephalon, Inc. announced that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Salmedix, Inc. for approximately $160 million cash; the company is required to pay an additional $40 ...
-
Sandoz, Inc. to Drop Challenge to PROVIGIL(R) Patent
(05/04/2005)
Cephalon, Inc. reported that Sandoz, Inc. has notified Cephalon that it will no longer challenge Cephalon's U.S. particle-size modafinil patent. Instead, Sandoz said it intends to convert its abbreviated new drug application (ANDA) for approval of a ...
-
Cephalon, Inc. and CIMA LABS INC. Sign Definitive Merger Agreement
(11/07/2003)
Cash Merger for $34 Per CIMA Share; Provides Cephalon with Drug Delivery Technologies; Will Accelerate Development and Launch of New Pharmaceutical Products
Cephalon, Inc. and CIMA LABS INC. announced that they have signed a definitive merger agreement under which Cephalon will acquire all the outstanding common shares of CIMA for $34 per share in cash.The total value of the transaction is approximately ...
|
|
|
|
|
Top
